Gefitinib for the treatment of non-small-cell lung cancer. (Q37738913)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Gefitinib for the treatment of non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Lynn Campbell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Nicholas Thatcher

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

1343-1357

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20426712%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Single-dose clinical pharmacokinetic studies of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

In vitro metabolism of gefitinib in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Cytochrome P450-dependent metabolism of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Biological and clinical implications of EGFR mutations in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.481283